United States
Print page content Print
Increase text size Decrease text size
Text Size

ZYLEXIS®

Help keep a stressed horse from becoming a sick horse

ZYLEXIS is an inactivated (killed) Parapox Ovis Virus Immunomodulator that has demonstrated efficacy and safety in stimulating the horse’s immune response to aid in the reduction of equine upper respiratory disease associated with EHV-1 and/or EHV-4 infections.

Expand All
  • DEMONSTRATED EFFICACY

    • Aids in the reduction of upper respiratory disease associated with equine herpesvirus types 1 and 4
    • ZYLEXIS treated horses showed significantly lower purulent nasal discharge (p<0.01) and clinical signs (p<0.01) than non-treated control horses1
    • Less days of mucopurulent nasal discharge were seen in ZYLEXIS treated horses vs. the control group1
    • Decreased nasal discharge scores may indicate less bacterial infections following EHV 1 & 4 infections

    DEMONSTRATED SCIENCE

    • A study of the Parapox Ovis Virus Immunomodulator in horses has shown an improvement in immune response that is useful in reducing severity and duration of viral disease2
    • Parapox Ovis Virus activates immune cells, stimulates phagocytosis and induces expression of cytokines; the messenger proteins that stimulate production of interferon and immune cells in a number of species3,4,5,6,7

    DEMONSTRATED SAFETY

    • None of the three-hundred and thirty-three ZYLEXIS treated horses had visible or palpable reactions at the injection site or systemic reactions8
    • ZYLEXIS is indicated for use in healthy horses over 4 months of age
  • Dose:

    • One 2 mL injection on days 0, 2 & 9 by intramuscular route

    When to Use:

    • Treatment is recommended during disease episodes or prior to stress-inducing situations. Retreatment is recommended during subsequent disease episodes or prior to stress-inducing situations
    • EHV 1 & 4 infections can be easily triggered by common stressors to horses including trailering, competition, breeding and environmental changes

    Directions: Aseptically rehydrate the freeze-dried component with the sterile diluent provided, shake well and administer 2 mL intramuscularly. Repeat the 2 mL dose on days 2 and 9 following the initial dose. Retreatment is recommended during subsequent disease episodes or prior to stress-inducing situations

    Precautions: Store at 2°- 8° C. Do not freeze. Use entire contents when first opened. Sterilized syringes and needles should be used to administer this immunomodulator. Do not administer within 21 days before slaughter. In case of anaphylaxis, administer epinephrine or equivalent.

  • Q. What is ZYLEXIS?
     A. ZYLEXIS is an inactivated (killed) Parapox Ovis Virus Immunomodulator administered intramuscularly (IM).

    Q: What are the indications for ZYLEXIS ?
    A: ZYLEXIS is indicated to aid in the reduction of upper respiratory disease associated with EHV 1 & 4 viral infections. This product is indicated for use in horses only.

    Q: When do I use it?
    A: ZYLEXIS may be administered to horses prior to being subjected to possible stress and during disease episodes. EHV can be easily triggered by common stressors to horses including trailering, competition, breeding and environmental changes.

    Q. What is the recommended dose?
    A. Dosing consists of one 2 mL IM injection on days 0, 2 & 9. Retreatment is recommended during subsequent disease episodes or prior to stress inducing situations.

    Q: Is ZYLEXIS safe?
    A: ZYLEXIS has undergone testing in a field safety trial in the US in 333 horses of various breeds ranging in age from 4 months to 20 years. No adverse events were reported8.

    Q: How often should I use ZYLEXIS?
    A: ZYLEXIS may be administered during subsequent disease episodes or before potentially stress-inducing events such as trailering, competition, breeding, racing or environmental changes.

    Q: Can I use ZYLEXIS in foals?
    A: Yes. ZYLEXIS is indicated for healthy horses over 4 months of age.

  • REFERENCES:

    1. Data on File, Zoetis Study No. Equine 1-98
    2. Ziebell KL, Steinmann H, Kretzdorn D, et. al. The use of Baypamun N in crowding associated infectious respiratory disease: Efficacy of Baypamun N (freeze dried product) in 4-10 month old horses. Zentralbl Veterinarmed B. 1997;44:529-536.
    3. Forster R,Wolf G, Mayr A. Highly attenuated poxviruses induce functional priming of neutrophils in vitro. Arch Virol 1994;136:219-226.
    4. Friebe A, Siegling A, Friedrichs S, et. al. Immunomodulatory effects of inactivated parapoxvirus ovis (orf virus) on human peripheral immune cells; Induction of cytokine secretion in monocytes and Th 1-like cells. J Virol 2004;78:9400-9411.
    5. Winnicka A, Klucinski W, Kawiak J, et. al. Effect of Baypamun on blood leucocytes in normal and dexamathasone treated goats. J Vet med A Physiol Pathol Clin Med 2000;47:385-394.
    6. Weber O, Siegling A, Friebe A, et al. Inactivated parapoxvirus ovis (orf virus) has antiviral activity against hepatitis B virus and herpes simplex virus. J Gen Virol 2003;84:1843-1852.
    7. Mayr A. Development of a non-immunising, paraspecific vaccine from attenuated pox viruses: A new type of vaccine. Microbiologica 2003;26:7-12.
    8. Data on File, Zoetis Study No. Nov. 20, 2000